Eterna Therapeutics Inc (ERNA) earnings · next report Nov 6, 2026
Next report
Fri, Nov 6, 2026
Time not announced · In 2 days
Quarter ended Sep 2026
- EPS consensus
- −$3.84 Range −$3.84 – −$3.841 analysts
- Revenue consensus
- $0 Range $0 – $01 analysts
EPS estimate trend
- 90 days ago$0.00
- 60 days ago−$3.84
- 30 days ago−$3.84
- 7 days ago−$3.84
- Now−$3.84
Last 30 days: 0 up, 0 down revisions.
Date and consensus: EODHD earnings calendar and estimates, refreshed every 6 hours. “Confirmed” means the provider lists the report session, which it sets once the company announces; “Estimated” is the provider’s expected date.
Follow ERNA into its report
Save it to a free watchlist (no card). Alerts when the date moves or results land are part of Pro.
Earnings move
- Options price in (Nov 6)
- — No options snapshot for this report yet (taken daily in the 7 days before a report, for stocks with listed options).
- Average move after earnings
- ±66.6% Absolute close-to-close move, 1 report
Options-implied move: the at-the-money straddle (call + put) on the first expiry after the report, divided by the stock’s close, from EODHD end-of-day option chains. It is what the options market prices as the absolute move to that expiry, not a forecast of direction. Move: close before the news → close after it (before the open: prior close → report-day close; after the close: report-day close → next close), adjusted for splits and dividends, from EODHD end-of-day prices. Reports with an unannounced time are not averaged: both candidate moves are stored instead. Per-report moves, gaps, moves vs SPY and the sector, beat/miss asymmetry and implied vs actual are in Lician Pro below.
Latest result
EPSGAAP
−$3.40
vs −$3.30 est. −3.0%
GAAP diluted EPS, SEC 10-Q
Revenue
—
No revenue consensus stored
EPS actuals are checked against the SEC filing and the company’s earnings press release (8-K EX-99.1). A company that reports only GAAP EPS is graded on its SEC diluted EPS; one that reports adjusted EPS is graded on the provider’s adjusted figure when the release confirms it. A figure that matches neither is shown as unverified, with no beat or miss. Revenue actuals come from the SEC filing of the same quarter where we have it.
Beat / miss history
- Missed EPS 3 quarters in a row
- Beat EPS in 0 of 3
- Aug 12, 2026MissEPS −$3.40GAAP vs −$3.30 −3.0%Rev — vs —
- May 11, 2026MissEPS −$6.95GAAP vs −$1.95 −256.4%Rev — vs —
- Nov 7, 2025MissEPS −$0.15GAAP vs $0.00 —Rev — vs —
| Reported | Quarter | EPS est. | EPS actual | Surprise | Revenue est. | Revenue | Surprise |
|---|---|---|---|---|---|---|---|
| Aug 12, 2026 | Jun 2026 | −$3.30 | −$3.40GAAP | −3.0% | — | — | — |
| May 11, 2026 | Mar 2026 | −$1.95 | −$6.95GAAP | −256.4% | — | — | — |
| Nov 7, 2025 | Sep 2025 | $0.00 | −$0.15GAAP | — | — | — | — |
Only 3 reported quarters are stored for ERNA so far. Older quarters are added as we load each company’s earnings history; nothing is filled in by estimate.
Earnings documents
No earnings 8-K (item 2.02) is stored for this report yet. All ERNA filings: SEC filings.
Documents link to SEC EDGAR. Lician does not publish earnings-call transcripts.
Healthcare peers with similar quant ratings
ERNA among 532 rated Healthcare stocks (Lician quant rating, Nov 4, 2026). How the rating works
- QTTB earnings5.00 · Strong Buy · stock
- AVAH earnings4.99 · Strong Buy · stock
- CDNA earnings4.98 · Strong Buy · stock
- HALO earnings4.97 · Strong Buy · stock
- OSCR earnings4.97 · Strong Buy · stock
- REGN earnings4.95 · Strong Buy · stock
- CON earnings4.94 · Strong Buy · stock
- PACS earnings4.94 · Strong Buy · stock
| Quarter | Revenue | EPS | YoY |
|---|---|---|---|
| Q2 FY26 | — | −$3.40 | — |
| Q1 FY26 | — | −$6.95 | — |
| Q3 FY25 | — | −$0.15 | — |
| Q2 FY25 | — | −$0.61 | — |
Eterna Therapeutics Inc (ERNA) is a biotechnology company listed on NASDAQ.
Latest reported ERNA revenue for 2024-12-31 was $582.0K. Net income was -$44.5M. Revenue was up 755.9% from 2023-12-31 to 2024-12-31. ERNA currently screens at market cap $6.9M.
When the next ERNA 8-K Item 2.02 lands, this page should move. Until then the SEC archive is the source.
The change that matters: Revenue was up 755.9% from 2023-12-31 to 2024-12-31. An earnings headline that ignores that move is noise.
Not investment advice. Full ERNA research stays on the stock page; the tape stays on the quote page.
ERNA earnings FAQ
When is ERNA's next earnings date?
Eterna Therapeutics Inc (ERNA) is expected to report on Fri, Nov 6, 2026. This is the provider’s estimated date; the company has not confirmed it. Consensus EPS is −$3.84.
Did ERNA beat earnings estimates last quarter?
No. On Aug 12, 2026 Eterna Therapeutics Inc (ERNA) reported adjusted EPS of −$3.40 against a −$3.30 consensus (−3.0%), a miss.
How often does ERNA beat EPS estimates?
Eterna Therapeutics Inc (ERNA) beat the EPS consensus in 0 of its last 3 reported quarters.
What are ERNA's latest revenue and net income?
Latest cached Eterna Therapeutics Inc (ERNA) revenue for Dec 31, 2024 was $582.0K. Net income was -$44.5M. Statements: https://lician.com/financials/erna
What is ERNA's latest diluted EPS?
Latest cached Eterna Therapeutics Inc (ERNA) diluted EPS for Dec 31, 2024 was -$3.26.
What period does the latest ERNA earnings print cover?
The latest cached Eterna Therapeutics Inc (ERNA) earnings print covers Dec 31, 2024. The prior cached period on this page is Dec 31, 2023.
How did ERNA revenue change from the prior cached period?
Cached Eterna Therapeutics Inc (ERNA) revenue was up 755.9% from $68.0K (Dec 31, 2023) to $582.0K (Dec 31, 2024). Statements: https://lician.com/financials/erna
Where are ERNA earnings listed?
Cached earnings facts for Eterna Therapeutics Inc (ERNA) are listed at https://lician.com/earnings/erna. Statements: https://lician.com/financials/erna
Not investment advice.